Department of Clinical Studies, School of Veterinary Medicine of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Vet Comp Oncol. 2010 Sep;8(3):196-208. doi: 10.1111/j.1476-5829.2010.00222.x.
A dose-intensified/dose-dense chemotherapy protocol for canine lymphoma was designed and implemented at the Veterinary Hospital of the University of Pennsylvania. In this study, we describe the clinical characteristics, prognostic factors, efficacy and toxicity in 130 dogs treated with this protocol. The majority of the dogs had advanced stage disease (63.1% stage V) and sub-stage b (58.5%). The median time to progression (TTP) and lymphoma-specific survival were 219 and 323 days, respectively. These results are similar to previous less dose-intense protocols. Sub-stage was a significant negative prognostic factor for survival. The incidence of toxicity was high; 53.9 and 45% of the dogs needed dose reductions and treatment delays, respectively. Dogs that required dose reductions and treatment delays had significantly longer TTP and lymphoma-specific survival times. These results suggest that dose density is important, but likely relative, and needs to be adjusted according to the individual patient's toxicity for optimal outcome.
宾夕法尼亚大学兽医院设计并实施了一种犬淋巴瘤的强化/密集化疗方案。在这项研究中，我们描述了 130 只接受该方案治疗的犬的临床特征、预后因素、疗效和毒性。大多数犬患有晚期疾病（63.1%为 V 期）和亚期 b（58.5%）。进展时间（TTP）和淋巴瘤特异性生存中位数分别为 219 天和 323 天。这些结果与以前剂量不那么密集的方案相似。亚期是生存的一个显著负预后因素。毒性发生率较高；53.9%和 45%的犬分别需要减少剂量和治疗延迟。需要减少剂量和治疗延迟的犬 TTP 和淋巴瘤特异性生存时间明显更长。这些结果表明，剂量密度很重要，但可能是相对的，需要根据个体患者的毒性进行调整，以达到最佳疗效。
